NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma Co N.V. held its 2026 Annual General Meeting, where shareholders approved the 2026 Employee Stock Purchase Plan (ESPP). The ESPP allows eligible employees to purchase up to 1,150,000 ordinary shares at a 15% discount. Additionally, shareholders approved the 2025 annual accounts, discharged directors from liability, appointed Deloitte Accountants B.V. as auditor, re-appointed two non-executive directors, and extended the Board's authorization to issue ordinary shares until June 2, 2031.

NewAmsterdam Pharma announced it will present data on obicetrapib, its oral, non-statin medicine for cardiovascular disease, at the National Lipid Association (NLA) 2026 Scientific Sessions from June 11-14, 2026. The presentations will highlight obicetrapib's potential as a novel therapy for hypercholesterolemia, covering safety, efficacy, and impact on kidney function from various clinical trials. The company is developing obicetrapib to address limitations of current LDL-lowering treatments.

NewAmsterdam Pharma announced that its management will participate in two upcoming investor conferences in June 2026. CEO Michael Davidson and Executive Vice President, Head of Investor Relations, Matthew Philippe, will host fireside chats at both the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts and replays of the presentations will be accessible via the company's investor relations website.

NewAmsterdam Pharma announced that its management will participate in two upcoming investor conferences. The BofA Securities 2026 Health Care Conference will feature a fireside chat on May 12, 2026, with the CFO, CCO, and EVP, Head of Investor Relations. The RBCCM Global Healthcare Conference on May 20, 2026, will include a fireside chat with the CEO and EVP, Head of Investor Relations. Live webcasts and replays will be available on the company's investor relations website.

NewAmsterdam Pharma reported a net loss of $48.4 million for Q1 2026, an increase from $39.5 million in Q1 2025, while revenue remained flat at $3.0 million. The company maintained a strong cash position of $707.3 million as of March 31, 2026. Significant clinical progress includes an interim analysis for the PREVAIL Phase 3 trial planned for Q4 2026, with results expected in Q1 2027, and topline data from the RUBENS Phase 3 trial anticipated by year-end 2026. Regulatory approval decisions for obicetrapib in Europe are expected in the second half of 2026.

NewAmsterdam Pharma reported an increased net loss of $(48.44) million for the first quarter of 2026, compared to $(39.53) million in the prior year, with basic and diluted net loss per share worsening to $(0.40). This occurred despite a slight revenue increase to $3.04 million and an improved operating loss of $(58.42) million. The company also noted a change in the valuation method for its Public Warrant liability due to decreased market activity.

NewAmsterdam Pharma Company N.V. announced its Annual General Meeting of Shareholders will be held on June 2, 2026, in Amsterdam. The agenda includes key corporate governance items such as the adoption of the 2025 Dutch statutory annual accounts and the discharge of directors from liability. Shareholders will also vote on the reappointment of two non-executive directors, the instruction and ratification of Deloitte Accountants B.V. as auditor for 2026, and the extension of the Board's authorization to issue shares and limit pre-emption rights. Additionally, approval for the 2026 Employee Stock Purchase Plan and an advisory vote on 2025 executive compensation are on the ballot.

NewAmsterdam Pharma announced that its Compensation Committee approved the grant of inducement equity awards to five non-executive new hires. The awards include 50,400 share options with an exercise price of $28.43, vesting over four years, and 15,400 restricted stock units (RSUs), vesting over three years. These grants were made under the 2024 Inducement Plan to attract new talent.

NewAmsterdam Pharma Company N.V. announced that Chief Accounting Officer Louise Kooij will depart the company effective August 31, 2026. A separation agreement was executed on April 24, 2026, outlining her severance package. This includes a lump sum payment equal to twelve months of her base salary and a pro-rated 2026 annual cash bonus. Additionally, the company agreed to extend the vesting of her outstanding stock options and restricted stock unit awards through January 10, 2027, with the exercise period for vested options expiring on February 10, 2027.